Anzeige
Mehr »
Dienstag, 12.08.2025 - Börsentäglich über 12.000 News
Diese Aktie liegt in der Turbo-Zone - und könnte der Gold-Gewinner 2025/26 werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JKQ4 | ISIN: CA29668H7085 | Ticker-Symbol:
NASDAQ
12.08.25 | 20:17
1,915 US-Dollar
+0,26 % +0,005
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ESSA PHARMA INC Chart 1 Jahr
5-Tage-Chart
ESSA PHARMA INC 5-Tage-Chart

Aktuelle News zur ESSA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiESSA Pharma to distribute $80 million to shareholders ahead of merger1
MiEssa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders1
31.07.ESSA Pharma Inc. - 8-K, Current Report2
ESSA PHARMA Aktie jetzt für 0€ handeln
23.07.ESSA Pharma to seek court approval for cash distribution to shareholders1
23.07.ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders1
23.07.ESSA Pharma Inc. - 8-K, Current Report1
14.07.ESSA Pharma to be acquired by XenoTherapeutics in all-cash deal3
14.07.ESSA Pharma Inc. - 8-K, Current Report5
14.07.ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction219SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:...
► Artikel lesen
08.05.ESSA Pharma GAAP EPS of -$0.141
08.05.ESSA Pharma Inc. - 8-K, Current Report1
08.05.ESSA Pharma Inc. - 10-Q, Quarterly Report5
08.05.ESSA Pharma Inc: ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025126Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 ...
► Artikel lesen
06.03.Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders216SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company...
► Artikel lesen
06.03.ESSA Pharma Inc. - 8-K, Current Report-
11.02.ESSA Pharma Inc: ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024182Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb....
► Artikel lesen
17.12.24ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024200Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER...
► Artikel lesen
12.11.24ESSA Pharma: NBC-Anlegerclub feiert schnelle +23% Rendite!447Der No Brainer Club (NBC) hat erneut sein Gespür für unterbewertete Biotech-Perlen unter Beweis gestellt. Mit ESSA Pharma konnten Mitglieder in diesem fulminanten Biotech-Herbst innerhalb weniger Tage...
► Artikel lesen
01.11.24Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma1.248CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15. VS...
► Artikel lesen
01.11.24ESSA Pharma Inc: ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer180Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1